Frequently reported TEAEs
| Patients, n (%) | RZB 150 mg N=483 | Placebo N=481 |
| TEAEs reported for ≥2% of patients in either group | ||
| Nasopharyngitis | 16 (3.3) | 14 (2.9) |
| Upper respiratory tract infection | 12 (2.5) | 20 (4.2) |
| Increased ALT | 13 (2.7) | 10 (2.1) |
| Increased AST | 10 (2.1) | 7 (1.5) |
| Headache | 10 (2.1) | 8 (1.7) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; RZB, risankizumab; TEAE, treatment-emergent adverse events.